Pharmaceuticals · 2022 · 20 citations · 23 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyViral InfectionsViral StructureAntiviral Drug DesignAntiviral Drug MechanismsAntiviral Mechanisms Of ActionAntiviral Structure-activity RelationshipsAntiviral TherapeuticsAssayViral Entry InhibitorsViral Fusion Inhibitors
Respiratory syncytial virus (RSV) causes acute respiratory infections, thus, posing a serious threat to the health of infants, children, and elderly people. In this study, we have discovered a series of potent RSV entry inhibitors with the (-)-borneol scaffold. The active compounds 3b, 5a, 5c, 7b, 9c, 10b, 10c, and 14b were found to exhibit activity against RSV A strain A2 in HEp-2 cells. The most active substances, 3b (IC50 = 8.9 μM, SI = 111) and 5a (IC50 = 5.0 μM, SI = 83), displayed more potency than the known antiviral agent Ribavirin (IC50 = 80.0 μM, SI = 50). Time-of-addition assay and temperature shift studies demonstrated that compounds 3b, 5a, and 6b inhibited RSV entry, probably by interacting with the viral F protein that mediated membrane fusion, while they neither bound to G protein nor inhibited RSV attachment to the target cells. Appling procedures of molecular modeling and molecular dynamics, the binding mode of compounds 3b and 5a was proposed. Taken together, the results of this study suggest (-)-borneol esters to be promising lead compounds for developing new anti-RSV agents.
23
Density-functional thermochemistry. III. The role of exact exchange
Axel D. Becke · The Journal of Chemical Physics · 1993 · 102.8K citations
Natural Sciences, Chemistry, Physics +13
VMD: Visual molecular dynamics
William Humphrey, Andrew Dalke, Klaus Schulten · Journal of Molecular Graphics · 1996 · 66.6K citations
Helen M. Berman, Tammy Battistuz, Talapady N. Bhat et al. · Acta Crystallographica Section D Biological Crystallography · 2002 · 2.6K citations